drugset / Trial / NCT07123103
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
The primary purpose of the study is to characterize the safety and tolerability of XB371. The dose-escalation cohorts and Part B of the expansion cohorts are non-randomized. Part A of the expansion cohorts is randomized.
Timeline
- Start
- 2025-08-18
- Primary completion
- 2027-11
- Completion
- 2028-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | XB371 | Unknown | — | Intravenous |